
Keywords: prostatic neoplasms; prostate-specific antigen; brachytherapy; androgen antagonists; disease-free survival; ADT; androgen deprivation therapy; bDFS; biochemical disease-free survival; BF; biochemical failure; EBRT; external beam radiotherapy; LDR-BT; low